Flamingo-01 Phase III GP2 Product Press Releases Email Alerts
Greenwich LifeSciences
  • ABOUT
    • MANAGEMENT TEAM
    • BOARD OF DIRECTORS
  • TECHNOLOGY
    • OUR GLSI-100 CANCER IMMUNOTHERAPY PRODUCT
    • CANCER AND IMMUNOTHERAPY OVERVIEW
  • CLINICAL TRIALS
    • COMPLETED CLINICAL TRIALS
    • FLAMINGO-01 PHASE III CLINICAL TRIAL
  • INVESTORS & MEDIA
    • OVERVIEW
    • NEWS & EVENTS
    • COMPANY INFO
    • STOCK INFO
    • SEC FILINGS
    • GOVERNANCE
  • CONTACT
  • ABOUT
    • MANAGEMENT TEAM
    • BOARD OF DIRECTORS
  • TECHNOLOGY
    • OUR GLSI-100 CANCER IMMUNOTHERAPY PRODUCT
    • CANCER AND IMMUNOTHERAPY OVERVIEW
  • CLINICAL TRIALS
    • COMPLETED CLINICAL TRIALS
    • FLAMINGO-01 PHASE III CLINICAL TRIAL
  • INVESTORS & MEDIA
    • OVERVIEW
    • NEWS & EVENTS
    • COMPANY INFO
    • STOCK INFO
    • SEC FILINGS
    • GOVERNANCE
  • CONTACT

Stock Information

Nasdaq: GLSI

Investors

  • Overview
  • News & Events
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Presentations
    • FAQ
  • Stock Info
  • SEC Filings
  • Governance

By proceeding to use this website, you consent to our use of cookies as described in our Privacy Policy.

Email Alerts

Sign up Now

Sign me up for:

  • Tear Sheet
  • RSS Feed
Logo of Greenwich LifeSciences.

Copyright © 2025

Greenwich LifeSciences, Inc.

ABOUT
TECHNOLOGY
CLINICAL TRIALS
INVESTORS & MEDIA
CONTACT
X logo
Privacy Policy
Disclaimer
Sitemap
Logo of Greenwich LifeSciences.

Copyright © 2025

Greenwich LifeSciences, Inc.

ABOUT
TECHNOLOGY
CLINICAL TRIALS
INVESTORS & MEDIA
CONTACT
Disclaimer
Privacy Policy
Sitemap
X logo

Market Data copyright © 2025 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.